@article{de0fedb216ea41b289920f882e310a13,
title = "Nampt/PBEF/Visfatin Regulates Insulin Secretion in β Cells as a Systemic NAD Biosynthetic Enzyme",
abstract = "Intracellular nicotinamide phosphoribosyltransferase (iNampt) is an essential enzyme in the NAD biosynthetic pathway. An extracellular form of this protein (eNampt) has been reported to act as a cytokine named PBEF or an insulin-mimetic hormone named visfatin, but its physiological relevance remains controversial. Here we show that eNampt does not exert insulin-mimetic effects in vitro or in vivo but rather exhibits robust NAD biosynthetic activity. Haplodeficiency and chemical inhibition of Nampt cause defects in NAD biosynthesis and glucose-stimulated insulin secretion in pancreatic islets in vivo and in vitro. These defects are corrected by administration of nicotinamide mononucleotide (NMN), a product of the Nampt reaction. A high concentration of NMN is present in mouse plasma, and plasma eNampt and NMN levels are reduced in Nampt heterozygous females. Our results demonstrate that Nampt-mediated systemic NAD biosynthesis is critical for β cell function, suggesting a vital framework for the regulation of glucose homeostasis.",
keywords = "HUMDISEASE, SIGNALING",
author = "Revollo, {Javier R.} and Antje K{\"o}rner and Mills, {Kathryn F.} and Akiko Satoh and Tao Wang and Antje Garten and Biplab Dasgupta and Yo Sasaki and Cynthia Wolberger and Townsend, {R. Reid} and Jeffrey Milbrandt and Wieland Kiess and Imai, {Shin ichiro}",
note = "Funding Information: We thank P. Bickel for 3T3-L1 and HIB-1B cells, W. Yokoyama and C. Nicchitta for Dhfr and Ppl cDNAs respectively, G. Gokel for a fluorometer, G.W. Sherrow for insulin measurements, M. Case for mass spectrometry analysis, and R. Tauscher and A. Berthold for technical assistance. We also thank N. Abumrad, I. Boime, J. Shaffer, and T. Baranski for critical comments and suggestions and the members of the Imai and Kiess labs for their help and encouragement. J.R.R. is a fellow supported by the Lucille P. Markey Special Emphasis Pathway in Human Pathology. A.K. and W.K. are supported by grants from the Deutsche Forschungsgemeinschaft KFO152: “Atherobesity” projects BE 1264/10-1 (to W.K.) and KO 3512/1-1 (to A.K), the Translational Centre for Regenerative Medicine (project 1082MN), and the German Diabetes Association (to A.K.). J.M. is supported by grants from the Muscular Dystrophy Association and National Institutes of Health (NS36358). R.R.T. is supported in part by the National Center for Research Resources (P41RR00945) and National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK52574). S.I. is an Ellison Medical Foundation Scholar in Aging and is also supported by grants from the National Institute on Aging (AG024150), American Diabetes Association, Juvenile Diabetes Research Foundation, Washington University Clinical Nutrition Research Unit (DK56341), and the National Center for Research Resources (C06RR015502). J.M. and C.W. are members of the scientific advisory board of Sirtris Pharmaceuticals, Inc. S.I. and J.R.R. are holders of intellectual property rights regarding the uses of Nampt and NMN, one of which is licensed to Sirtris Pharmaceuticals, Inc. ",
year = "2007",
month = nov,
day = "7",
doi = "10.1016/j.cmet.2007.09.003",
language = "English",
volume = "6",
pages = "363--375",
journal = "Cell metabolism",
issn = "1550-4131",
number = "5",
}